Detalles de la búsqueda
1.
A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity.
Acta Neuropathol Commun;
12(1): 101, 2024 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38902810
2.
Adaption of neurosurgical resection patterns for pediatric low-grade glioma spanning two decades-Report from the German LGG-studies 1996-2018.
Cancer Med;
13(12): e7417, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38923198
3.
Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
Neuro Oncol;
2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38743009
4.
Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
J Neurooncol;
168(2): 317-332, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630384
5.
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Nat Med;
30(5): 1500, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467878
6.
Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
J Neurooncol;
166(1): 99-112, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38184819
7.
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
BMC Cancer;
24(1): 147, 2024 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291372
8.
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Nat Med;
30(1): 207-217, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37978284
9.
Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.
Nat Med;
30(1): 306, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875569
10.
Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Neuro Oncol;
26(1): 25-37, 2024 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37944912
11.
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Neuro Oncol;
26(3): 407-416, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38146999
12.
Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.
J Neurooncol;
165(3): 467-478, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37999877
13.
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
J Neurooncol;
164(3): 617-632, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37783879
14.
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
N Engl J Med;
389(12): 1108-1120, 2023 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733309
15.
Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
Neuro Oncol;
25(11): 1920-1931, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738646
16.
Genetical and epigenetical profiling identifies two subgroups of pineal parenchymal tumors of intermediate differentiation (PPTID) with distinct molecular, histological and clinical characteristics.
Acta Neuropathol;
146(6): 853-856, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37776353
17.
Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
J Clin Oncol;
41(33): 5174-5183, 2023 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37643378
18.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Lancet Oncol;
24(8): 925-935, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541273
19.
Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies.
Clin Pharmacol Ther;
114(4): 904-913, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441736
20.
MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
Nat Commun;
14(1): 4533, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37500667